238 related articles for article (PubMed ID: 33610719)
1. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
Wang J; Wang L
Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; Beauregard A; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2016 Mar; 23(3):243-56. PubMed ID: 26731686
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
Labrie F; Archer DF; Koltun W; Vachon A; Young D; Frenette L; Portman D; Montesino M; Côté I; Parent J; Lavoie L; BSc AB; Martel C; Vaillancourt M; Balser J; Moyneur É;
Menopause; 2018 Nov; 25(11):1339-1353. PubMed ID: 30358731
[TBL] [Abstract][Full Text] [Related]
4. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
5. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
[TBL] [Abstract][Full Text] [Related]
7. Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Villa P; Tagliaferri V; Amar ID; Cipolla C; Ingravalle F; Scambia G; Ricciardi W; Lanzone A
Gynecol Endocrinol; 2020 Jun; 36(6):535-539. PubMed ID: 31847628
[TBL] [Abstract][Full Text] [Related]
8. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
Labrie F; Archer DF; Bouchard C; Girard G; Ayotte N; Gallagher JC; Cusan L; Baron M; Blouin F; Waldbaum AS; Koltun W; Portman DJ; Côté I; Lavoie L; Beauregard A; Labrie C; Martel C; Balser J; Moyneur É;
Maturitas; 2015 May; 81(1):46-56. PubMed ID: 25771041
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
[TBL] [Abstract][Full Text] [Related]
10. Estradiol softgel inserts for the treatment of VVA symptoms: an expert opinion.
Liu JH; Bernick B; Mirkin S
Expert Opin Drug Deliv; 2020 Nov; 17(11):1573-1581. PubMed ID: 32877254
[TBL] [Abstract][Full Text] [Related]
11. Dehydroepiandrosterone intra vaginal administration for the management of postmenopausal vulvovaginal atrophy.
Archer DF
J Steroid Biochem Mol Biol; 2015 Jan; 145():139-43. PubMed ID: 25201455
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
13. Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F; Archer DF; Martel C; Vaillancourt M; Montesino M
Menopause; 2017 Nov; 24(11):1246-1256. PubMed ID: 28640161
[TBL] [Abstract][Full Text] [Related]
14. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
[TBL] [Abstract][Full Text] [Related]
16. Impact of vulvovaginal atrophy of menopause: prevalence and symptoms in Italian women according to the EVES study.
Nappi RE; Seracchioli R; Salvatore S; Cagnacci A; Di Paolantonio T; Busacca M;
Gynecol Endocrinol; 2019 May; 35(5):453-459. PubMed ID: 30700188
[TBL] [Abstract][Full Text] [Related]
17. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
Pickar JH; Amadio JM; Hill JM; Bernick BA; Mirkin S
Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
[TBL] [Abstract][Full Text] [Related]
19. The effect of vulvovaginal atrophy on women's quality of life from an Italian cohort of the EVES study.
Nappi RE; Di Carlo C; Becorpi AM; Gambacciani M; De Seta F; Ribaldone R; Benedetto C; Paoletti AM;
J Obstet Gynaecol; 2020 May; 40(4):512-519. PubMed ID: 31496326
[TBL] [Abstract][Full Text] [Related]
20. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
Portman D; Palacios S; Nappi RE; Mueck AO
Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]